[go: up one dir, main page]

CY1118435T1 - Παραγωγο μορφολινο νουκλεϊνικου οξεος - Google Patents

Παραγωγο μορφολινο νουκλεϊνικου οξεος

Info

Publication number
CY1118435T1
CY1118435T1 CY20171100027T CY171100027T CY1118435T1 CY 1118435 T1 CY1118435 T1 CY 1118435T1 CY 20171100027 T CY20171100027 T CY 20171100027T CY 171100027 T CY171100027 T CY 171100027T CY 1118435 T1 CY1118435 T1 CY 1118435T1
Authority
CY
Cyprus
Prior art keywords
morpholine
nuclear acid
acid producer
nucleic acid
provides
Prior art date
Application number
CY20171100027T
Other languages
English (en)
Inventor
Toshihiro Ueda
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of CY1118435T1 publication Critical patent/CY1118435T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ένα χρήσιμο παράγωγο μορφολινο νουκλεϊνικού οξέος για σύνθεση ενός ολιγομερούς μορφολινο νουκλεϊνικού οξέος. Η παρούσα εφεύρεση παρέχει μια ένωση που αντιπροσωπεύεται από τον παρακάτω γενικό τύπο (1) ή ένα άλας.
CY20171100027T 2010-09-30 2017-01-10 Παραγωγο μορφολινο νουκλεϊνικου οξεος CY1118435T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010220865 2010-09-30
PCT/JP2011/072407 WO2012043730A1 (ja) 2010-09-30 2011-09-29 モルホリノ核酸誘導体

Publications (1)

Publication Number Publication Date
CY1118435T1 true CY1118435T1 (el) 2017-06-28

Family

ID=45893168

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100027T CY1118435T1 (el) 2010-09-30 2017-01-10 Παραγωγο μορφολινο νουκλεϊνικου οξεος

Country Status (18)

Country Link
US (1) US8969551B2 (el)
EP (1) EP2623507B1 (el)
JP (1) JP5831455B2 (el)
KR (1) KR101764462B1 (el)
CN (1) CN103154009B (el)
CA (1) CA2813183C (el)
CY (1) CY1118435T1 (el)
DK (1) DK2623507T3 (el)
ES (1) ES2607603T3 (el)
HR (1) HRP20170028T1 (el)
HU (1) HUE030292T2 (el)
LT (1) LT2623507T (el)
PL (1) PL2623507T3 (el)
PT (1) PT2623507T (el)
RS (1) RS55610B1 (el)
SI (1) SI2623507T1 (el)
SM (2) SMT201700038T1 (el)
WO (1) WO2012043730A1 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228711A1 (en) 2004-06-28 2017-10-11 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
EP3404100A1 (en) 2008-10-24 2018-11-21 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
CN103003430A (zh) 2009-11-12 2013-03-27 西澳大利亚大学 反义分子和治疗疾病的方法
JP2013530154A (ja) * 2010-05-28 2013-07-25 サレプタ セラピューティクス， インコーポレイテッド 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013074834A1 (en) 2011-11-18 2013-05-23 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
ES2706198T3 (es) 2012-03-20 2019-03-27 Sarepta Therapeutics Inc Conjugados de ácido borónico de análogos de oligonucleótidos
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
JP6449231B2 (ja) 2013-03-14 2019-01-09 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
EP3662912A1 (en) 2013-03-15 2020-06-10 Sarepta Therapeutics, Inc. Improved dosages of eteplirsen for treating duchenne muscular dystrophy
DK3015467T3 (da) 2013-05-24 2025-02-10 Ajinomoto Kk Morpholino-oligonukleotidfremstillingsfremgangsmåde
KR20210088009A (ko) 2013-09-05 2021-07-13 사렙타 쎄러퓨틱스, 인코퍼레이티드 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
US9790495B2 (en) 2014-05-16 2017-10-17 Oregon State University Antisense antibacterial compounds and methods
EP3569252B1 (en) 2014-05-19 2021-12-15 Oregon State University Antisense antibacterial compounds and methods
EP3208277A4 (en) * 2014-10-14 2018-06-13 Ajinomoto Co., Inc. Morpholino oligonucleotide manufacturing method
WO2016108930A2 (en) * 2014-12-31 2016-07-07 Geller Bruce L Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
KR20240035901A (ko) 2015-05-19 2024-03-18 사렙타 쎄러퓨틱스 인코퍼레이티드 펩티드 올리고뉴클레오티드 콘주게이트
EP3851531A1 (en) 2015-06-01 2021-07-21 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
ES2907629T3 (es) * 2015-08-05 2022-04-25 Eisai R&D Man Co Ltd Un método para preparar un oligómero de fosforodiamidato sustancialmente puro diastereoisoméricamente, un oligómero de fosforodiamidato preparado mediante dicho método y una composición farmacéutica que comprende dicho oligómero de fosforodiamidato
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
CN108472504A (zh) * 2015-12-15 2018-08-31 萨勒普塔医疗公司 肽寡核苷酸缀合物
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11142764B2 (en) 2015-12-23 2021-10-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MX2018012695A (es) 2016-04-18 2019-06-20 Sarepta Therapeutics Inc Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido.
EP3449000A1 (en) 2016-04-29 2019-03-06 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
HUE066393T2 (hu) 2016-05-24 2024-07-28 Sarepta Therapeutics Inc Eljárás foszfordiamidát morfolino oligomerek elõállítására
WO2017205496A1 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing oligomers
KR20190009343A (ko) 2016-05-24 2019-01-28 사렙타 쎄러퓨틱스 인코퍼레이티드 에테플리센을 포함하는 약제학적 조성물
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
SG10202101836TA (en) 2016-05-24 2021-03-30 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
CN109152792B (zh) 2016-06-30 2021-09-14 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
WO2018057430A1 (en) 2016-09-20 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
JP7218361B2 (ja) * 2017-09-25 2023-02-06 サレプタ セラピューティクス， インコーポレイテッド 高速流動合成を介してホスホロジアミデートモルホリノオリゴマーを調製するための方法
EP3697910A4 (en) 2017-10-18 2021-07-14 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
KR20210008055A (ko) * 2018-05-10 2021-01-20 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
WO2021095875A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 オリゴ核酸化合物の製造方法
JPWO2021095874A1 (el) 2019-11-13 2021-05-20
CN116096724A (zh) * 2020-07-10 2023-05-09 常州合全药业有限公司 用于制备寡核苷酸的方法
JPWO2022230954A1 (el) * 2021-04-28 2022-11-03
CA3216839A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
US20240318179A1 (en) 2021-10-22 2024-09-26 Murdoch University Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2023127918A1 (ja) 2021-12-27 2023-07-06 日本新薬株式会社 オリゴ核酸化合物の製造方法
EP4486752A1 (en) * 2022-03-01 2025-01-08 Eisai R&D Management Co., Ltd. Bis-protected, activated guanine monomers
KR20240155352A (ko) 2022-03-17 2024-10-28 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머 접합체
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312834T1 (de) 1989-12-20 2005-12-15 Avi Biopharma Inc Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten
JP2005255530A (ja) * 2004-03-09 2005-09-22 Japan Science & Technology Agency ２−チオウリジン誘導体
EP2024499B1 (en) * 2006-05-10 2017-10-25 Sarepta Therapeutics, Inc. Oligonucleotide analogs having cationic intersubunit linkages
BRPI0819828A8 (pt) * 2007-11-15 2022-12-27 Avi Biopharma Inc Processo de síntese de oligômeros de morfolino
US8076476B2 (en) * 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits

Also Published As

Publication number Publication date
EP2623507B1 (en) 2016-11-02
RS55610B1 (sr) 2017-06-30
LT2623507T (lt) 2017-01-25
US8969551B2 (en) 2015-03-03
EP2623507A1 (en) 2013-08-07
DK2623507T3 (da) 2017-01-02
PT2623507T (pt) 2016-12-23
KR20130143045A (ko) 2013-12-30
EP2623507A4 (en) 2014-03-19
JP5831455B2 (ja) 2015-12-09
PL2623507T3 (pl) 2017-03-31
HUE030292T2 (en) 2017-04-28
JPWO2012043730A1 (ja) 2014-02-24
CN103154009B (zh) 2015-06-10
US20130197220A1 (en) 2013-08-01
SI2623507T1 (sl) 2017-04-26
HRP20170028T1 (hr) 2017-03-24
SMT201700038T1 (it) 2017-03-08
ES2607603T3 (es) 2017-04-03
SMT201700038B (it) 2017-03-08
CA2813183C (en) 2017-09-19
CN103154009A (zh) 2013-06-12
KR101764462B1 (ko) 2017-08-02
CA2813183A1 (en) 2012-04-05
WO2012043730A1 (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
CY1118435T1 (el) Παραγωγο μορφολινο νουκλεϊνικου οξεος
UA113643C2 (xx) N-цикліламіди як нематоциди
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
BR112015000160A2 (pt) fabricação de ácido 2-(5-bromo-4-(4-ciclopropil hidronaftalen-1-il)-4h-1,2,4-triazol-3-il-tio) acético
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CR20110474A (es) Derivados de benzofurano
CY1119121T1 (el) Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv
EA201290800A1 (ru) Гетероциклическое соединение
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
RS54730B1 (sr) Inhibitori beta sekretaze
EA201101099A1 (ru) Гербициды, полученные из циклопентадиона
EA200900945A1 (ru) Новый способ синтеза агомелатина
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
EA200900946A1 (ru) Новый способ синтеза агомелатина
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
CY1116974T1 (el) Παραγωγα 5-υδροξυπυριμιδινο-4-καρβοξαμιδιου
UY34075A (es) ?compuestos insecticidas a base de derivados de ariltioacetamida
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
AU2012310674B2 (en) Radioactive fluorine labeled compound
CY1117912T1 (el) Ενωσεις πυραζολιου ως αναστολεiς του συμμεταφορεα νατριου-γλυκοζης 1 (sglt1)
MX2017017022A (es) Metodo para la sintesis de derivados de rapamicina.
CY1119040T1 (el) Μεθοδος για την παρασκευη 1-([1,3]διοξολαν-4-υλομεθυλο)-1η-πυραζολ-3-υλαμινης
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης